AKB-6548: Phase Ib data

In a double-blind, placebo-controlled, multiple ascending-dose, U.S. Phase Ib trial in 33 healthy volunteers, once-daily oral AKB-6548 for 10 days was well tolerated with no serious adverse events. Ad...